Suggested remit: To appraise the clinical and cost effectiveness of mirvetuximab soravtansine within its marketing authorisation for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6442

Provisional Schedule

Committee meeting 04 November 2025
Expected publication 28 January 2026

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter

Stakeholders

Companies sponsors AbbVie (Mirvetuximab soravtansine)
Others Department of Health and Social Care
  NHS England
Patient carer groups Black Health Agency for Equality
  Cancer 52
  Cancer Black Care
  Eve Appeal
  Go Girls
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Ovacome
  Ovarian Cancer Action
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Target Ovarian Cancer
  Tenovus Cancer Care
  The Robin Cancer Trust
  Wellbeing of Women
  Women's Health Concern
Professional groups Association of Anaesthetists
  Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  British Association of Gynaecological Pathologists
  British Association of Surgical Oncology
  British Geriatrics Society
  British Gynaecological Cancer Society
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Society of Urogynaecology
  Cancer Research UK
  National Forum of Gynaecological Oncology Nurses
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Obstetricians and Gynaecologists
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Accord (paclitaxel)
  Alliance Healthcare (paclitaxel)
  Baxter (pegylated liposomal doxorubicin hydrochloride (PLDH) monotherapy)
  Bristol-Myers Squibb Pharmaceuticals Ltd (paclitaxel)
  Fresenius Kabi Ltd (paclitaxel)
  Pfizer Ltd (paclitaxel)
  Seacross Pharmaceuticals Ltd (paclitaxel)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Gynaecological Cancer Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
19 March 2025 The company have asked NICE to delay this appraisal so that they can incorporate additional data into their submission. NICE have agreed to this request. This appraisal will now be considered by the NICE Technology Appraisal Committee at a meeting on 4 November 2025
09 January 2025 Invitation to participate
05 November 2024 - 03 December 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6442
05 November 2024 In progress. Scoping commencing
22 September 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual